Researchers have discovered a difference between radiation-sensitive and radiation-resistant tumors that could be utilized to assess tumor response, potentially sparing some patients of the toxic side effects of ineffective radiation therapy.
Innovate UK award BioMoti, Pharmidex and Queen Mary University of London Biomedical Catalyst grant of £662,222
BioMoti, Pharmidex and Queen Mary University of London awarded grant to support preclinical studies of new therapeutic approaches for hard to treat tumors.
A blood test could predict how men diagnosed with advanced prostate cancer respond to targeted disease treatments.
Metabolomics could be used to identify cancerous tumors in those undergoing surgery for renal masses.